Medical data platform company JNPMEDI (CEO Kwun-ho Jeong) and global clinical partner LSK Global PS (CEO Young-jak Lee) announced that they signed a contract to use Maven Docs, Korea's first clinical trial document preparation and management solution.
JNPMEDI Launches 'Maven Docs' in Collaboration with LSK Global PS
LSK Global PS, Enterprise Agreement for the Use of Maven Docs No. 1 for Efficient Documentation and Management
Maven Docs Expect Industry Innovation with Standardization of Various Clinical Trial Documents and Support for Document Management through Data Linkage.
Korea's first clinical trial document preparation and management solution, Maven Docs, signed a contract (in order from left) JNPMEDI business development team leader Hyung-joon Kim, Chief Business Officer Min-seok Kim, CEO Kwun-ho Jeong and LSK Global Pharma Service CEO Young-jak Lee, Vice President Byung-kwan Park, and Managing Director Young-ki Lee.
Maven Docs is a solution released by the two companies after about a year of development through the MOU signing in October last year. The solution was developed to address the inefficiencies caused by frequent corrections, even though the preparation of clinical trial documents proceeds with a rigorous review and approval process.
Maven Docs standardizes the preparation of various clinical trial documents such as clinical trial plans, case records, clinical trial manuals, and consent forms, and supports simple document management through data linkage. Maven Docs' document creation function, Composer, enables easy document creation based on form standardization and data linkage, and allows users to set document viewing and download rights through the Viewer function. In addition, in compliance with 21 CFR part 11, the FDA's regulation on electronic records and electronic signatures, it provides optimized electronic signatures for clinical trials without purchasing separate programs.
Young-jak Lee, CEO of LSK Global PS, said, "The various documents required in the clinical trial process go through a complex process, and if the contents between related documents or errors occur, time and cost can increase, and we expect to provide faster and more stable clinical trial services through efficient document creation and management."
"Maven Docs is a representative service that meets the company's value to streamline the entire process of clinical trials through digital transformation," said Kwun-ho Jeong, CEO of JNPMEDI. "We will lead a paradigm shift in the clinical trial industry through upgrading the Maven platform and various services in the future."